| | |
Mean
|
SD
|
SE
|
ANOVA
|
95% CI
|
Minimum
|
Maximum
|
|---|
| | | | | | |
Lower limit
|
Upper limit
| | |
|---|
|
Total amount of prescription dose (per 5 months)
|
FC
|
142.9
|
80.2
|
8.0
|
*
|
127.0
|
158.7
|
10.5
|
437.8
|
|
SF
|
132.1
|
84.0
|
9.3
|
*
|
113.6
|
150.5
|
5.3
|
399.0
|
|
LC
|
208.7
|
89.9
|
8.0
|
*
|
192.8
|
224.5
|
35.0
|
462.0
|
| |
Total
|
166.8
|
91.9
|
5.2
| |
156.5
|
177.1
|
5.3
|
462.0
|
|
Total prescription dose/starting dose
|
FC
|
0.6
|
0.4
|
0.0
|
*
|
0.6
|
0.7
|
0.0
|
2.0
|
|
SF
|
1.1
|
0.7
|
0.1
|
*
|
1.0
|
1.3
|
0.0
|
3.4
|
|
LC
|
1.8
|
0.8
|
0.1
|
*
|
1.7
|
1.9
|
0.3
|
4.0
|
| |
Total
|
1.2
|
0.8
|
0.0
| |
1.2
|
1.3
|
0.0
|
4.0
|
|
Phosphate change rate (%) [(Pi_end − Pi_week_0) × 100/Pi_week_0]
|
FC
|
2.9
|
31.5
|
3.1
| |
−3.4
|
9.1
|
−45.1
|
116.3
|
|
SF
|
−10.8
|
22.6
|
2.5
|
*
|
−15.8
|
−5.9
|
−54.0
|
48.8
|
|
LC
|
−3.2
|
27.8
|
2.5
| |
−8.1
|
1.7
|
−59.5
|
152.4
|
| |
Total
|
−3.3
|
28.3
|
1.6
| |
−6.4
|
−0.1
|
−59.5
|
152.4
|
|
Number of times ferritin ≥300 ng/mL
|
FC
|
0.1
|
0.4
|
0.0
| |
0.0
|
0.2
|
0.0
|
4.0
|
|
SF
|
2.3
|
1.5
|
0.2
|
*
|
1.9
|
2.6
|
0.0
|
5.0
|
|
LC
|
0.0
|
0.2
|
0.0
| |
0.0
|
0.1
|
0.0
|
2.0
|
| |
Total
|
0.6
|
1.3
|
0.1
| |
0.5
|
0.8
|
0.0
|
5.0
|
|
Total amount of ESA dose (μg) #
|
FC
|
440.0
|
567.6
|
56.5
| |
327.9
|
552.0
|
0.0
|
3960.0
|
|
SF
|
265.7
|
339.2
|
37.5
|
*
|
191.2
|
340.2
|
0.0
|
1880.0
|
|
LC
|
424.7
|
445.4
|
39.7
| |
346.2
|
503.2
|
0.0
|
2640.0
|
| |
Total
|
387.5
|
469.9
|
26.7
| |
334.9
|
440.1
|
0.0
|
3960.0
|
- Total amount of ESA dose was calculated using an epoetin:darbepoetin:CERA conversion ratio of 200:1:1
-
SD standard deviation, SE standard error
- *used as indicators for p values
